All Outputs (5)

Tremelimumab for the treatment of malignant mesothelioma (2015)
Journal Article
Guazzelli, A., Hussain, M., Krstic- Demonacos, M., & Mutti, L. (2015). Tremelimumab for the treatment of malignant mesothelioma. Expert Opinion on Biological Therapy, 15(12), 1819-1829. https://doi.org/10.1517/14712598.2015.1116515

Introduction: Tremelimumab demonstrated therapeutic activity in different malignancies, including malignant pleural mesothelioma (MPM); however, continued research could improve the therapeutic index of this agent. Areas covered: This review descr... Read More about Tremelimumab for the treatment of malignant mesothelioma.

The expanded p53 interactome as a predictive model for cancer therapy (2015)
Journal Article
Hussain, M., Tian, K., Mutti, L., Krstic-Demonacos, M., & Schwartz, J. (2015). The expanded p53 interactome as a predictive model for cancer therapy. Genomics and computational biology, 1(1), e20. https://doi.org/10.18547/gcb.2015.vol1.iss1.e20

The tumour suppressor gene TP53 is implicated in the majority of all human cancers, thus pivotal to genomic integrity. Even though over 72,000 PubMed publications are linked with the keyword p53 and this number is continuously increasing, due to... Read More about The expanded p53 interactome as a predictive model for cancer therapy.

The role of microenvironment and immunity in drug response in leukemia (2015)
Journal Article
Bakker, E., Qattan, M., Mutti, L., Demonacos, C., & Krstic- Demonacos, M. (2015). The role of microenvironment and immunity in drug response in leukemia. BBA - Molecular Cell Research, 1863(3), 414-426. https://doi.org/10.1016/j.bbamcr.2015.08.003

Leukemia is a cancer of the white blood cells, with over 54,000 new cases per year diagnosed worldwide and a 5-year survival rate below 60%. This highlights a need for research into the mechanisms behind its etiology and causes of therapy failure. Th... Read More about The role of microenvironment and immunity in drug response in leukemia.

Novel therapies for cancer treatment : designing high affinity and selectivity ligands against SIRT1 (2015)
Presentation / Conference
Al-Sudani, B., Krstic- Demonacos, M., & Ragazzon, P. (2015, June). Novel therapies for cancer treatment : designing high affinity and selectivity ligands against SIRT1. Poster presented at EuroMedLab Paris 2015, Paris, France

The word ‘sirtuin’ (SIR) stands for Silent Information Regulator. SIRT1 is the most studied mammalian sirtuin and predominantly localises to the nucleus. Many sirtuins targets are involved in cancer and in many types of cancers, SIRT1 is found to be... Read More about Novel therapies for cancer treatment : designing high affinity and selectivity ligands against SIRT1.

Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile (2015)
Journal Article
Kuroda, K., Fukuda, T., Isogai, H., Okumura K, K., Krstic-Demonacos, M., & Isogai, E. (2015). Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile. International Journal of Oncology, 46(4), 1516-1526. https://doi.org/10.3892/ijo.2015.2887

Metabolic reprogramming is one of the hallmarks of cancer and can be targeted by therapeutic agents. We previously reported that cathelicidin-related or modified antimicrobial peptides, such as FF/CAP18, have antiproliferative effects on the squamous... Read More about Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile.